Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374).

BACKGROUND: Inavolisib is a potent and selective PI3Ka inhibitor that promotes degradation of mutated p110a. We report safety from a phase I/Ib dose-escalation/-expansion study (GO39374; NCT03006172) of inavolisib alone or in combination therapies in PIK3CA-mutated, hormone receptor (HR)-positive, H...

Descripción completa

Detalles Bibliográficos
Autores: Gambardella, V, Accordino, MK, Bedard, PL, Cervantes, A, Hamilton, E, Italiano, A, Kalinsky, K, Krop, IE, Oliveira, M, Saura, C, Schmid, P, Turner, NC, Varga, A, Fernandez-Saranillo, A, Jin, Y, Royer-Joo, S, Peters, U, Shankar, N, Schutzman, JL, Juric, D, Jhaveri, KL
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:INCLIVA
Repositorio:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
OAI Identifier:oai:incliva.fundanetsuite.com:p20098
Acceso en línea:https://incliva.portalinvestigacion.com/publicaciones/20098
Access Level:acceso abierto
Palabra clave:PI3K inhibitor
PIK3CA-mutated
breast cancer
hormone receptor-positive
safety
id ES_da5965ef8ce259e2dfe3f5119b57bf30
oai_identifier_str oai:incliva.fundanetsuite.com:p20098
network_acronym_str ES
network_name_str España
repository_id_str
spelling Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374).Gambardella, VAccordino, MKBedard, PLCervantes, AHamilton, EItaliano, AKalinsky, KKrop, IEOliveira, MSaura, CSchmid, PTurner, NCVarga, AFernandez-Saranillo, AJin, YRoyer-Joo, SPeters, UShankar, NSchutzman, JLJuric, DJhaveri, KLPI3K inhibitorPIK3CA-mutatedbreast cancerhormone receptor-positivesafetyBACKGROUND: Inavolisib is a potent and selective PI3Ka inhibitor that promotes degradation of mutated p110a. We report safety from a phase I/Ib dose-escalation/-expansion study (GO39374; NCT03006172) of inavolisib alone or in combination therapies in PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative advanced breast cancer. PATIENTS AND METHODS: Patients received inavolisib [oral once daily (od)] alone, with letrozole (2.5 mg od) or fulvestrant (500 mg intramuscularly 4 weekly) ± palbociclib (125 mg od for 21/28 days); metformin was included in one arm. PRIMARY ENDPOINT: safety and tolerability. RESULTS: At data cutoff (1 January 2024), 190 patients had been treated, of which 179 (94.2%) had discontinued study treatment, mainly due to progressive disease [146 (76.8%)]. Treatment-related any-grade and grade 3-5 adverse events (AEs) occurred in 181 (95.3%) and 107 (56.3%) patients, respectively. Inavolisib-related AEs led to inavolisib withdrawal in 5 (2.6%) and dose reductions/interruptions in 103 (54.2%) patients. Hyperglycemia, diarrhea, stomatitis (grouped terms), and rash (grouped terms) occurred in 129 (67.9%), 124 (65.3%), 93 (48.9%), and 47 (24.7%) patients, respectively. Hyperglycemia, diarrhea, and stomatitis mainly occurred early in treatment, and were manageable with supportive measures (including oral antihyperglycemic agents, common antidiarrheal medications, and dexamethasone mouthwash, respectively) and/or inavolisib dose modifications (dose interruptions with or without dose reductions). Hyperglycemia remained frequent in patients with risk factors, despite early metformin treatment. Rash was mostly grade 1 and required no treatment. Patients treated for =1 year [n = 65 (34.2%)] demonstrated encouraging long-term tolerability. CONCLUSIONS: Inavolisib alone or in combination with HR-positive breast cancer therapies demonstrated a manageable safety and tolerability profile, which supports its ongoing development.ELSEVIER2025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://incliva.portalinvestigacion.com/publicaciones/20098ESMO OpenISSN: 20597029reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVAinstname:INCLIVAInglésinfo:eu-repo/semantics/openAccessoai:incliva.fundanetsuite.com:p200982026-06-07T16:35:31Z
dc.title.none.fl_str_mv Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374).
title Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374).
spellingShingle Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374).
Gambardella, V
PI3K inhibitor
PIK3CA-mutated
breast cancer
hormone receptor-positive
safety
title_short Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374).
title_full Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374).
title_fullStr Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374).
title_full_unstemmed Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374).
title_sort Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374).
dc.creator.none.fl_str_mv Gambardella, V
Accordino, MK
Bedard, PL
Cervantes, A
Hamilton, E
Italiano, A
Kalinsky, K
Krop, IE
Oliveira, M
Saura, C
Schmid, P
Turner, NC
Varga, A
Fernandez-Saranillo, A
Jin, Y
Royer-Joo, S
Peters, U
Shankar, N
Schutzman, JL
Juric, D
Jhaveri, KL
author Gambardella, V
author_facet Gambardella, V
Accordino, MK
Bedard, PL
Cervantes, A
Hamilton, E
Italiano, A
Kalinsky, K
Krop, IE
Oliveira, M
Saura, C
Schmid, P
Turner, NC
Varga, A
Fernandez-Saranillo, A
Jin, Y
Royer-Joo, S
Peters, U
Shankar, N
Schutzman, JL
Juric, D
Jhaveri, KL
author_role author
author2 Accordino, MK
Bedard, PL
Cervantes, A
Hamilton, E
Italiano, A
Kalinsky, K
Krop, IE
Oliveira, M
Saura, C
Schmid, P
Turner, NC
Varga, A
Fernandez-Saranillo, A
Jin, Y
Royer-Joo, S
Peters, U
Shankar, N
Schutzman, JL
Juric, D
Jhaveri, KL
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv PI3K inhibitor
PIK3CA-mutated
breast cancer
hormone receptor-positive
safety
topic PI3K inhibitor
PIK3CA-mutated
breast cancer
hormone receptor-positive
safety
description BACKGROUND: Inavolisib is a potent and selective PI3Ka inhibitor that promotes degradation of mutated p110a. We report safety from a phase I/Ib dose-escalation/-expansion study (GO39374; NCT03006172) of inavolisib alone or in combination therapies in PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative advanced breast cancer. PATIENTS AND METHODS: Patients received inavolisib [oral once daily (od)] alone, with letrozole (2.5 mg od) or fulvestrant (500 mg intramuscularly 4 weekly) ± palbociclib (125 mg od for 21/28 days); metformin was included in one arm. PRIMARY ENDPOINT: safety and tolerability. RESULTS: At data cutoff (1 January 2024), 190 patients had been treated, of which 179 (94.2%) had discontinued study treatment, mainly due to progressive disease [146 (76.8%)]. Treatment-related any-grade and grade 3-5 adverse events (AEs) occurred in 181 (95.3%) and 107 (56.3%) patients, respectively. Inavolisib-related AEs led to inavolisib withdrawal in 5 (2.6%) and dose reductions/interruptions in 103 (54.2%) patients. Hyperglycemia, diarrhea, stomatitis (grouped terms), and rash (grouped terms) occurred in 129 (67.9%), 124 (65.3%), 93 (48.9%), and 47 (24.7%) patients, respectively. Hyperglycemia, diarrhea, and stomatitis mainly occurred early in treatment, and were manageable with supportive measures (including oral antihyperglycemic agents, common antidiarrheal medications, and dexamethasone mouthwash, respectively) and/or inavolisib dose modifications (dose interruptions with or without dose reductions). Hyperglycemia remained frequent in patients with risk factors, despite early metformin treatment. Rash was mostly grade 1 and required no treatment. Patients treated for =1 year [n = 65 (34.2%)] demonstrated encouraging long-term tolerability. CONCLUSIONS: Inavolisib alone or in combination with HR-positive breast cancer therapies demonstrated a manageable safety and tolerability profile, which supports its ongoing development.
publishDate 2025
dc.date.none.fl_str_mv 2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://incliva.portalinvestigacion.com/publicaciones/20098
url https://incliva.portalinvestigacion.com/publicaciones/20098
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv ELSEVIER
publisher.none.fl_str_mv ELSEVIER
dc.source.none.fl_str_mv ESMO Open
ISSN: 20597029
reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname:INCLIVA
instname_str INCLIVA
reponame_str r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
collection r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869421569263009792
score 15.811543

Similares en LA Referencia